Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience
Articolo
Data di Pubblicazione:
2016
Citazione:
Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience / Meattini, I., Desideri, I., Di Cataldo, V., Francolini, G., De Luca Cardillo, C., Scotti, V., Loi, M., Detti, B., Mangoni, M., Agresti, B., Baldazzi, V., Greto, D., Casella, D., Bernini, M., Sanchez, L.J., Orzalesi, L., Nori, J., Fambrini, M., Bianchi, S., Livi, L.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 12:9(2016), pp. 1117-1124. [10.2217/fon-2015-0059]
Abstract:
AIM: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT.
RESULTS: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%.
CONCLUSION: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.
RESULTS: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%.
CONCLUSION: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.
Tipologia CRIS:
Articolo su rivista
Keywords:
concomitant radiotherapy; eribulin mesylate; metastatic breast cancer; safety; toxicity
Elenco autori:
Meattini, Icro; Desideri, Isacco; Di Cataldo, Vanessa; Francolini, Giulio; De Luca Cardillo, Carla; Scotti, Vieri; Loi, Mauro; Detti, Beatrice; Mangoni, Monica; Agresti, Benedetta; Baldazzi, Valentina; Greto, Daniela; Casella, Donato; Bernini, Marco; Sanchez, Luis Jose; Orzalesi, Lorenzo; Nori, Jacopo; Fambrini, Massimiliano; Bianchi, Simonetta; Livi, Lorenzo
Link alla scheda completa:
Pubblicato in: